Safety
-
Myozyme (alglucosidase alfa)
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – July 2012
ADVERSE REACTIONS
Postmarketing Experience
- nephrotic syndrome and proteinuria
-
-







